Skip to content
RecruitingPhase 1

Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department

NCT06085937 · Lindsay Maguire, MD

Recruiting
Status
Accepting participants
Phase 1
Phase
50
Target enrolment
2
Study sites
1 US states

What it is testing

Summary

There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Measured over 2 hours

  • Provider and Nursing Attitudes toward use of Ketamine for Suicidal Patients in the ED [Feasibility]

    Measured over 2 hours

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Acutely Suicidality ("yes" answer to any of items 4 or 5 on C-SSRS "Suicidal Ideation" category) * Require inpatient stabilization for SI or actions based on clinical observation and interview * Are accepted for psychiatric stabilization at the University of Kansas Medical Center's Strawberry Hill campus * Have a Glasgow Coma Score (GCS) of 15 * Age 18-65 Exclusion Criteria: * Current or past history of psychosis * Current or recent (past 4 weeks) symptoms of mania/hypomania as defined by Young Mania Rating Scale (YRMS) score of 12 or greater * History of ketamine use disorder * History of liver transplant * Pregnancy or breastfeeding * Imprisonment or inability to consent * Positive urine drug screen or serum alcohol level * Hypertension (SBP \> 160 or DBP \> 100 before administration of ketamine) * Hypotension (SBP \< 90) * Presence of acute medical condition requiring admission to medical service * Allergy, intolerance, or previous adverse reaction to ketamine * Patient has 8+ lifetime ketamine exposures * The treating physician determines that the patient is not a good candidate for the study (e.g. medical condition/procedure, medication that would contradindicate ketamine treatment)

Where

2 study sites

FacilityCityRegionCountry
University of Kansas Strawberry Hill CampusKansas CityKansasUnited States
University of Kansas Medical Center Emergency DepartmentKansas CityKansasUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06085937 on ClinicalTrials.gov →

Last updated in the registry 2026-04-15. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits